Benjamin Pyles
Benjamin Pyles (BS, MS, MBA) designed the world’s first epigenetic modifying therapeutic as a treatment for Angelman’s Syndrome—work which has netted 3 patents for the University of California, Davis. His work on therapeutic delivery technologies have resulted in: proto-treatments for various viral diseases, co-treatments for antibiotic resistant bacterial infections (i.e., MRSA), as well as therapeutics for glioblastoma and breast cancer.